Skip to main content
Top
Published in: Hematology and Cell Therapy 2/1999

01-04-1999 | Original articles

The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell® technology

Authors: C. Chabannon, G. Novakovitch, J.-L. Blache, S. Olivero, J. Camerlo, D. Genre, D. Maraninchi, P. Viens

Published in: Hematology and Cell Therapy | Issue 2/1999

Login to get access
Metadata
Title
The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell® technology
Authors
C. Chabannon
G. Novakovitch
J.-L. Blache
S. Olivero
J. Camerlo
D. Genre
D. Maraninchi
P. Viens
Publication date
01-04-1999
Publisher
Springer Paris
Published in
Hematology and Cell Therapy / Issue 2/1999
Print ISSN: 1269-3286
Electronic ISSN: 1279-8509
DOI
https://doi.org/10.1007/s00282-999-0078-7

Other articles of this Issue 2/1999

Hematology and Cell Therapy 2/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine